Asthma

>

Latest News

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD / image credit courtesy of Upstream Bio
Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD

July 11th 2025

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

 Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows / image courtesy of Karolinska Institutet
Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows

July 2nd 2025

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma
Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

June 17th 2025

 Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma
Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma

June 16th 2025

Half of Adults with Severe Asthma Treated with Tezepelumab Discontinue OCS Use at 52 Weeks: WAYFINDER / image credit Kings College London David J Jackson, MBBS, PhD
Half of Adults with Severe Asthma Treated with Tezepelumab Discontinue OCS Use at 52 Weeks: Phase 3b WAYFINDER Trial

May 22nd 2025

More News

© 2025 MJH Life Sciences

All rights reserved.